Merck & Company Inc (MRK)vsARS Pharmaceuticals, Inc (SPRY)
MRK
Merck & Company Inc
$144.85
+0.64%
HEALTHCARE · Cap: $355.10B
SPRY
ARS Pharmaceuticals, Inc
$4.76
-5.93%
HEALTHCARE · Cap: $558.89M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 56832% more annual revenue ($66.57B vs $116.93M). MRK leads profitability with a 4.8% profit margin vs -184.2%. MRK earns a higher WallStSmart Score of 36/100 (F).
MRK
Hold36
out of 100
Grade: F
SPRY
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-73.7%
Fair Value
$82.84
Current Price
$144.85
$62.01 premium
Intrinsic value data unavailable for SPRY.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Revenue surging 114.2% year-over-year
Areas to Watch
Trading at 8.5x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
Trading at 36.6x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bull Case : SPRY
The strongest argument for SPRY centers on Revenue Growth. Revenue growth of 114.2% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Bear Case : SPRY
The primary concerns for SPRY are EPS Growth, Market Cap, Piotroski F-Score. Debt-to-equity of 13.72 is elevated, increasing financial risk.
Key Dynamics to Monitor
MRK profiles as a value stock while SPRY is a hypergrowth play — different risk/reward profiles.
SPRY carries more volatility with a beta of 1.00 — expect wider price swings.
SPRY is growing revenue faster at 114.2% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (36/100 vs 31/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →ARS Pharmaceuticals, Inc
HEALTHCARE · BIOTECHNOLOGY · USA
ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine aerosol with absorption technology for patients and their families at risk of severe allergic reactions to food, medication, and insect stings. The company is headquartered in San Diego, California.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?